KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Equity Income: 2016-2024

Historic Equity Income for Jazz Pharmaceuticals (JAZZ) over the last 9 years, with Dec 2024 value amounting to -$1.7 million.

  • Jazz Pharmaceuticals' Equity Income rose 83.51% to -$47,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$890,000, marking a year-over-year increase of 57.72%. This contributed to the annual value of -$1.7 million for FY2024, which is 44.83% up from last year.
  • As of FY2024, Jazz Pharmaceuticals' Equity Income stood at -$1.7 million, which was up 44.83% from -$3.0 million recorded in FY2023.
  • Jazz Pharmaceuticals' 5-year Equity Income high stood at -$714,000 for FY2021, and its period low was -$9.9 million during FY2022.
  • Its 3-year average for Equity Income is -$4.9 million, with a median of -$3.0 million in 2023.
  • In the last 5 years, Jazz Pharmaceuticals' Equity Income surged by 75.89% in 2021 and then plummeted by 1,289.50% in 2022.
  • Over the past 5 years, Jazz Pharmaceuticals' Equity Income (Yearly) stood at -$3.0 million in 2020, then surged by 75.89% to -$714,000 in 2021, then tumbled by 1,289.50% to -$9.9 million in 2022, then skyrocketed by 69.67% to -$3.0 million in 2023, then surged by 44.83% to -$1.7 million in 2024.